International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy

Heidrun Potschka; Andrea Fischer; Wolfgang Löscher; Ned Patterson; Sofie Bhatti; Mette Berendt; Luisa De Risio; Robyn Farquhar; Sam Long; Paul Mandigers; Kaspar Matiasek; Karen Muñana; Akos Pakozdy; Jacques Penderis; Simon Platt; Michael Podell; Clare Rusbridge; Veronika Stein; Andrea Tipold; Holger A. Volk

doi:10.1186/s12917-015-0465-y

International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy

Heidrun Potschka, Andrea Fischer, Wolfgang Löscher, Ned Patterson, Sofie Bhatti, Mette Berendt, Luisa De Risio, Robyn Farquhar, Sam Long, Paul Mandigers, Kaspar Matiasek, Karen Muñana, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger A. Volk

Veterinary Clinical Sciences

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

Common criteria for the diagnosis of drug resistance and the assessment of outcome are needed urgently as a prerequisite for standardized evaluation and reporting of individual therapeutic responses in canine epilepsy. Thus, we provide a proposal for the definition of drug resistance and partial therapeutic success in canine patients with epilepsy. This consensus statement also suggests a list of factors and aspects of outcome, which should be considered in addition to the impact on seizures. Moreover, these expert recommendations discuss criteria which determine the validity and informative value of a therapeutic trial in an individual patient and also suggest the application of individual outcome criteria. Agreement on common guidelines does not only render a basis for future optimization of individual patient management, but is also a presupposition for the design and implementation of clinical studies with highly standardized inclusion and exclusion criteria. Respective standardization will improve the comparability of findings from different studies and renders an improved basis for multicenter studies. Therefore, this proposal provides an in-depth discussion of the implications of outcome criteria for clinical studies. In particular ethical aspects and the different options for study design and application of individual patient-centered outcome criteria are considered.

Original language	English (US)
Article number	177
Journal	BMC Veterinary Research
Volume	11
Issue number	1
DOIs	https://doi.org/10.1186/s12917-015-0465-y
State	Published - Aug 28 2015

Bibliographical note

Funding Information:
Following reimbursements, fees and funding have been received by the authors in the last three years and have been declared in the competing interest section. WL, CR, RGF, HAV, KM, MP and JP have received fees for acting as a consultant for Boehringer Ingelheim (WL, KM, MP: consultancy during development and approval of imepitoin; CR: pain consultancy; RGF, JP, HAV: consultancy pre and post launch of imepitoin). AT has been an advisor for Boehringer Ingelheim. SFMB, HAV and AT have been responsible principal investigator of several research studies concerning imepitoin financed by Boehringer Ingelheim. SFMB, HAV, JP, HP, MB, CR and AF received speaking fees from Boehringer Ingelheim. HP received consulting and speaking fees and funding for a collaborative project from Eisai Co. LTD. HAV received funding for a collaborative project from Desitin and Nestlé Purina Research. AF and LDR received reimbursements from Boehringer Ingelheim. LDR has received consulting and speaking fees from Vetoquinol. MP has received consultant fees for Aratana. The other authors declared that they have no competing interests.

Funding Information:
The authors are grateful to all owners of epileptic pets and veterinary colleagues who have inspired the group to create consensus statements. We would especially like to thank Professor Simon Shorvon for the critical review of the consensus statements. His great insight has been immensely helpful. The authors also would like to thank the research office for assessing the manuscript according to the Royal Veterinary College’s code of good research practice (Authorisation Number – CCS_ 01026). This study was not financially supported by any organization or grant.

Publisher Copyright:
© 2015 Potschka et al.

Keywords

Dog
Epilepsy
Epileptic seizure
Treatment

Publisher link

10.1186/s12917-015-0465-y

Find It

Find It at U of M Libraries

Cite this

Potschka, H., Fischer, A., Löscher, W., Patterson, N., Bhatti, S., Berendt, M., De Risio, L., Farquhar, R., Long, S., Mandigers, P., Matiasek, K., Muñana, K., Pakozdy, A., Penderis, J., Platt, S., Podell, M., Rusbridge, C., Stein, V., Tipold, A., & Volk, H. A. (2015). International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy. BMC Veterinary Research, 11(1), Article 177. https://doi.org/10.1186/s12917-015-0465-y

Potschka, H, Fischer, A, Löscher, W, Patterson, N, Bhatti, S, Berendt, M, De Risio, L, Farquhar, R, Long, S, Mandigers, P, Matiasek, K, Muñana, K, Pakozdy, A, Penderis, J, Platt, S, Podell, M, Rusbridge, C, Stein, V, Tipold, A & Volk, HA 2015, 'International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy', BMC Veterinary Research, vol. 11, no. 1, 177. https://doi.org/10.1186/s12917-015-0465-y

@article{e5918da873de4ef8ad6536292cfaa698,

title = "International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy",

abstract = "Common criteria for the diagnosis of drug resistance and the assessment of outcome are needed urgently as a prerequisite for standardized evaluation and reporting of individual therapeutic responses in canine epilepsy. Thus, we provide a proposal for the definition of drug resistance and partial therapeutic success in canine patients with epilepsy. This consensus statement also suggests a list of factors and aspects of outcome, which should be considered in addition to the impact on seizures. Moreover, these expert recommendations discuss criteria which determine the validity and informative value of a therapeutic trial in an individual patient and also suggest the application of individual outcome criteria. Agreement on common guidelines does not only render a basis for future optimization of individual patient management, but is also a presupposition for the design and implementation of clinical studies with highly standardized inclusion and exclusion criteria. Respective standardization will improve the comparability of findings from different studies and renders an improved basis for multicenter studies. Therefore, this proposal provides an in-depth discussion of the implications of outcome criteria for clinical studies. In particular ethical aspects and the different options for study design and application of individual patient-centered outcome criteria are considered.",

keywords = "Dog, Epilepsy, Epileptic seizure, Treatment",

author = "Heidrun Potschka and Andrea Fischer and Wolfgang L{\"o}scher and Ned Patterson and Sofie Bhatti and Mette Berendt and {De Risio}, Luisa and Robyn Farquhar and Sam Long and Paul Mandigers and Kaspar Matiasek and Karen Mu{\~n}ana and Akos Pakozdy and Jacques Penderis and Simon Platt and Michael Podell and Clare Rusbridge and Veronika Stein and Andrea Tipold and Volk, {Holger A.}",

note = "Funding Information: Following reimbursements, fees and funding have been received by the authors in the last three years and have been declared in the competing interest section. WL, CR, RGF, HAV, KM, MP and JP have received fees for acting as a consultant for Boehringer Ingelheim (WL, KM, MP: consultancy during development and approval of imepitoin; CR: pain consultancy; RGF, JP, HAV: consultancy pre and post launch of imepitoin). AT has been an advisor for Boehringer Ingelheim. SFMB, HAV and AT have been responsible principal investigator of several research studies concerning imepitoin financed by Boehringer Ingelheim. SFMB, HAV, JP, HP, MB, CR and AF received speaking fees from Boehringer Ingelheim. HP received consulting and speaking fees and funding for a collaborative project from Eisai Co. LTD. HAV received funding for a collaborative project from Desitin and Nestl{\'e} Purina Research. AF and LDR received reimbursements from Boehringer Ingelheim. LDR has received consulting and speaking fees from Vetoquinol. MP has received consultant fees for Aratana. The other authors declared that they have no competing interests. Funding Information: The authors are grateful to all owners of epileptic pets and veterinary colleagues who have inspired the group to create consensus statements. We would especially like to thank Professor Simon Shorvon for the critical review of the consensus statements. His great insight has been immensely helpful. The authors also would like to thank the research office for assessing the manuscript according to the Royal Veterinary College{\textquoteright}s code of good research practice (Authorisation Number – CCS_ 01026). This study was not financially supported by any organization or grant. Publisher Copyright: {\textcopyright} 2015 Potschka et al.",

year = "2015",

month = aug,

day = "28",

doi = "10.1186/s12917-015-0465-y",

language = "English (US)",

volume = "11",

journal = "BMC Veterinary Research",

issn = "1746-6148",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - International veterinary epilepsy task force consensus proposal

T2 - Outcome of therapeutic interventions in canine and feline epilepsy

AU - Potschka, Heidrun

AU - Fischer, Andrea

AU - Löscher, Wolfgang

AU - Patterson, Ned

AU - Bhatti, Sofie

AU - Berendt, Mette

AU - De Risio, Luisa

AU - Farquhar, Robyn

AU - Long, Sam

AU - Mandigers, Paul

AU - Matiasek, Kaspar

AU - Muñana, Karen

AU - Pakozdy, Akos

AU - Penderis, Jacques

AU - Platt, Simon

AU - Podell, Michael

AU - Rusbridge, Clare

AU - Stein, Veronika

AU - Tipold, Andrea

AU - Volk, Holger A.

N1 - Funding Information: Following reimbursements, fees and funding have been received by the authors in the last three years and have been declared in the competing interest section. WL, CR, RGF, HAV, KM, MP and JP have received fees for acting as a consultant for Boehringer Ingelheim (WL, KM, MP: consultancy during development and approval of imepitoin; CR: pain consultancy; RGF, JP, HAV: consultancy pre and post launch of imepitoin). AT has been an advisor for Boehringer Ingelheim. SFMB, HAV and AT have been responsible principal investigator of several research studies concerning imepitoin financed by Boehringer Ingelheim. SFMB, HAV, JP, HP, MB, CR and AF received speaking fees from Boehringer Ingelheim. HP received consulting and speaking fees and funding for a collaborative project from Eisai Co. LTD. HAV received funding for a collaborative project from Desitin and Nestlé Purina Research. AF and LDR received reimbursements from Boehringer Ingelheim. LDR has received consulting and speaking fees from Vetoquinol. MP has received consultant fees for Aratana. The other authors declared that they have no competing interests. Funding Information: The authors are grateful to all owners of epileptic pets and veterinary colleagues who have inspired the group to create consensus statements. We would especially like to thank Professor Simon Shorvon for the critical review of the consensus statements. His great insight has been immensely helpful. The authors also would like to thank the research office for assessing the manuscript according to the Royal Veterinary College’s code of good research practice (Authorisation Number – CCS_ 01026). This study was not financially supported by any organization or grant. Publisher Copyright: © 2015 Potschka et al.

PY - 2015/8/28

Y1 - 2015/8/28

N2 - Common criteria for the diagnosis of drug resistance and the assessment of outcome are needed urgently as a prerequisite for standardized evaluation and reporting of individual therapeutic responses in canine epilepsy. Thus, we provide a proposal for the definition of drug resistance and partial therapeutic success in canine patients with epilepsy. This consensus statement also suggests a list of factors and aspects of outcome, which should be considered in addition to the impact on seizures. Moreover, these expert recommendations discuss criteria which determine the validity and informative value of a therapeutic trial in an individual patient and also suggest the application of individual outcome criteria. Agreement on common guidelines does not only render a basis for future optimization of individual patient management, but is also a presupposition for the design and implementation of clinical studies with highly standardized inclusion and exclusion criteria. Respective standardization will improve the comparability of findings from different studies and renders an improved basis for multicenter studies. Therefore, this proposal provides an in-depth discussion of the implications of outcome criteria for clinical studies. In particular ethical aspects and the different options for study design and application of individual patient-centered outcome criteria are considered.

AB - Common criteria for the diagnosis of drug resistance and the assessment of outcome are needed urgently as a prerequisite for standardized evaluation and reporting of individual therapeutic responses in canine epilepsy. Thus, we provide a proposal for the definition of drug resistance and partial therapeutic success in canine patients with epilepsy. This consensus statement also suggests a list of factors and aspects of outcome, which should be considered in addition to the impact on seizures. Moreover, these expert recommendations discuss criteria which determine the validity and informative value of a therapeutic trial in an individual patient and also suggest the application of individual outcome criteria. Agreement on common guidelines does not only render a basis for future optimization of individual patient management, but is also a presupposition for the design and implementation of clinical studies with highly standardized inclusion and exclusion criteria. Respective standardization will improve the comparability of findings from different studies and renders an improved basis for multicenter studies. Therefore, this proposal provides an in-depth discussion of the implications of outcome criteria for clinical studies. In particular ethical aspects and the different options for study design and application of individual patient-centered outcome criteria are considered.

KW - Dog

KW - Epilepsy

KW - Epileptic seizure

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84940024604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940024604&partnerID=8YFLogxK

U2 - 10.1186/s12917-015-0465-y

DO - 10.1186/s12917-015-0465-y

M3 - Article

C2 - 26314300

AN - SCOPUS:84940024604

SN - 1746-6148

VL - 11

JO - BMC Veterinary Research

JF - BMC Veterinary Research

IS - 1

M1 - 177

ER -

International veterinary epilepsy task force consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this